<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Emtricitabine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Emtricitabine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Emtricitabine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11188" href="/d/html/11188.html" rel="external">see "Emtricitabine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13245" href="/d/html/13245.html" rel="external">see "Emtricitabine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708728"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Posttreatment acute exacerbation of hepatitis B:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine. If appropriate, initiation of anti-HBV therapy may be warranted.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F164630"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Emtriva</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F164648"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)</li></ul></div>
<div class="block doa drugH1Div" id="F164632"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: 200 mg once daily in combination with other antiretrovirals.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: 240 mg once daily in combination with other antiretrovirals.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational postexposure prophylaxis (nPEP) (off-label use)</b>: <b>Oral:</b> Capsule: 200 mg once daily; initiate therapy within 72 hours of exposure and continue for 28 days in combination with other antiretrovirals (3-drug regimen) <b>Note:</b> The fixed-dose emtricitabine and tenofovir disoproxil fumarate combination product is recommended for these components of the 3-drug regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="073e1ab6-e458-419d-abe6-bd0e545357ed">HIV-1 occupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 occupational postexposure prophylaxis (oPEP) (off-label use):</b>
<b>Oral:</b> Capsule: 200 mg once daily in combination with tenofovir disoproxil fumarate and raltegravir; initiate therapy as soon as possible after occupational exposure (and within 72 hours) and continue for 4 weeks; <b>Note:</b> The fixed-dose emtricitabine and tenofovir disoproxil fumarate combination product is recommended for these components of the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23917901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23917901'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990396"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Emtricitabine is primary eliminated by the kidney; dose adjustments are generally recommended to prevent accumulation in patients with kidney dysfunction, particularly when CrCl is &lt;30 mL/minute. Concomitant use of other medications that affect tubular creatinine secretion (eg, dolutegravir, cobicistat) may overestimate the severity of kidney impairment and should be considered prior to adjusting the dose of emtricitabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36504313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36504313'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Emtricitabine Dosage Adjustments for Altered Kidney Function: Oral:</b></p>
<table border="1" frame="border" rules="all">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left" rowspan="2">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Manufacturer's labeling</b></p></th>
<th align="left">
<p style="text-indent:0em;">Alternative recommendation<sup>a</sup></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Capsule</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Solution</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Capsule</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a </sup>Manufacturer's labeling contains the traditional dose adjustments aimed to provide equal exposures to those with normal kidney function. However, since emtricitabine is usually well tolerated, and the capsule dose adjustments involve prolonging the dosing interval (which can make adherence more difficult), the risks and benefits of the alternative recommendation (ie, no [or limited] dose adjustment) should be weighed on an individualized basis, with close monitoring for GI adverse effects (eg, nausea), as well as symptoms that could suggest more rare side effects (eg, lactic acidemia, pancreatitis, rhabdomyolysis) (Wood 2021).</p>
<p style="text-indent:0em;">
<sup>b </sup>Considerations may include but are not limited to: Use of emtricitabine as an individual component of an antiretroviral regimen versus as part of an emtricitabine-containing combination product (refer to combination product monographs for dosing recommendations); patient's ability to adhere to the regimen; availability/accessibility of formulations (capsules, oral solution); prior tolerability issues with emtricitabine; anticipated duration of use (Wood 2021; expert opinion).</p>
<p style="text-indent:0em;">
<sup>c </sup>Dialyzable (30%) (manufacturer's labeling).</p>
<p style="text-indent:0em;">
<sup>d </sup>When scheduled dose falls on a hemodialysis day, administer after hemodialysis.</p>
<p style="text-indent:0em;">
<sup>e </sup>Several combination products require “no dosage adjustment” in hemodialysis patients according to manufacturer's labeling (see specific combination monographs for more details).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">≥50 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;">No dose adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to &lt;50 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;">200 mg every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">120 mg every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary (Post 2017; Pozniak 2016; Valade 2014; expert opinion).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 to &lt;30 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;">200 mg every 72 hours</p></td>
<td align="left">
<p style="text-indent:0em;">80 mg every 24 hours</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Due to increased emtricitabine exposure, the manufacturer's recommended dose adjustments are generally preferred. However, in some situations<sup>b</sup> use of unadjusted doses (ie, 200 mg once daily for capsules) may be considered, along with frequent monitoring for adverse effects (Wood 2021; expert opinion).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;15 mL/minute (not on dialysis)</p></td>
<td align="left">
<p style="text-indent:0em;">200 mg every 96 hours</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hemodialysis, intermittent (thrice weekly)</p></td>
<td align="left">
<p style="text-indent:0em;">200 mg every 96 hours<sup>c,d</sup></p></td>
<td align="left">
<p style="text-indent:0em;">60 mg every 24 hours<sup>c,d</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Although emtricitabine exposure will be increased (Eron 2018), in some situations<sup>b,e</sup> use of unadjusted doses (ie, 200 mg once daily for capsules) may be considered, along with frequent monitoring for adverse effects (Eron 2018; HHS [adult] 2022; Sidman 2023).<sup>c,d</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Peritoneal dialysis</p></td>
<td align="left">
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling; may consider utilizing dose adjustments provided for hemodialysis patients (expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling; may consider utilizing dose adjustments provided for hemodialysis patients (expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">Due to increased emtricitabine exposure, the manufacturer's recommended dose adjustments for patients on hemodialysis are generally preferred for patients on peritoneal dialysis. However, although data is limited to one case report (Partosh 2023), in some situations<sup>b</sup> use of unadjusted doses (ie, 200 mg once daily for capsules) may be considered, along with frequent monitoring for adverse effects (expert opinion).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">There are no data available in patients on CRRT (has not been studied); however, no dosage adjustment is likely necessary since some emtricitabine removal by CRRT is expected based on its physicochemical characteristics and it is generally well tolerated; monitor frequently for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DOR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">There are no data available in patients on PIRRT (has not been studied); however, no dosage adjustment is likely necessary since some emtricitabine removal by PIRRT is expected based on its physicochemical characteristics and it is generally well-tolerated; monitor frequently for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DOR.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987550"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, not hepatically metabolized, so impact of hepatic impairment would be minimal.</p></div>
<div class="block doe drugH1Div" id="F164633"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F1729621"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13245" href="/d/html/13245.html" rel="external">see "Emtricitabine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to bioavailability differences, oral dosage forms are not bioequivalent; oral solution and capsules should <b>not</b> be interchanged on a mg:mg basis. Gene mutation and antiretroviral (ARV) resistance patterns should be evaluated (refer to https://www.iasusa.org/ for more information) when necessary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: Note:</b> Use in combination with other ARV agents. Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to &lt;3 months: Oral solution: 3 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents ≤17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution: 6 mg/kg/dose once daily; maximum daily dose: 240 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsules: Patient weight &gt;33 kg and able to swallow capsule whole: 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsules: 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution: 240 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days in combination with other ARV agents. Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to &lt;3 months: Oral solution: 3 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution: 6 mg/kg/dose once daily; maximum daily dose: 240 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsules: Patient weight &gt;33 kg and able to swallow capsule whole: 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: The combination product is recommended (see emtricitabine and tenofovir disoproxil fumarate monograph).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108457"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor clinical response and renal function closely. Dialysis: 30% of the dose is removed by hemodialysis (over 3 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;18 years: There are no specific dosage adjustments provided in the manufacturer's labeling; however, may consider a reduction in the dose and/or an increase in the dosing interval similar to dosage adjustments for adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 49 mL/minute: Capsule: 200 mg every 48 hours; oral solution: 120 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to 29 mL/minute: Capsule: 200 mg every 72 hours; oral solution: 80 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Capsule: 200 mg every 96 hours; oral solution: 60 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Capsule: 200 mg every 24 hours; solution: 240 mg every 24 hours; administer after hemodialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51108458"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustments are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F164598"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with combination therapy in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (7% to 30%; includes allergic skin rash, exfoliative rash, maculopapular rash, pruritus, pustular rash, urticaria, vesiculobullous rash)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (grades 3/4: 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (8% to 14%), diarrhea (9% to 23%), nausea (9% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (2% to 11%), asthenia (12% to 16%), dizziness (4% to 25%), headache (6% to 22%), insomnia (5% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (grades 3/4: 9% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (14%), rhinitis (12% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum glucose (grades 3/4: ≤3%), hyperglycemia (grades 3/4: ≤3%), increased serum triglycerides (grades 3/4: 4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (4% to 8%), increased serum amylase (grades 3/4: ≤8%), increased serum lipase (grades 3/4: ≤1%), vomiting (2% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (grades 3/4: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (grades 3/4: 2% to 5%), increased serum alkaline phosphatase (grades 3/4: 1%), increased serum aspartate aminotransferase (grades 3/4: 3% to 6%), increased serum bilirubin (grades 3/4: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (6% to 9%), fatigue (9%), neuropathy (≤4%), paresthesia (5% to 6%), peripheral neuritis (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3% to 5%), myalgia (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (5%), sinusitis (8%), upper respiratory tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Genitourinary: Glycosuria (grades 3/4)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Dermatologic: Skin discoloration</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperpigmentation (palms or soles) (Shirasaka 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Lactic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis (eosinophilic) (Lozier 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Howard 2019), pure red cell aplasia (Manickchund 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Exacerbation of hepatitis B (with discontinuation of therapy) (Mondou 2005), hepatomegaly with steatosis (severe)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immune reconstitution syndrome (IRIS: including IRIS-related hepatitis B flare and tinea-IRIS) (Arshad 2023, Mapesi 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Trigeminal neuralgia (Van Slyke 2018)</p></div>
<div class="block coi drugH1Div" id="F164612"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to emtricitabine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F164596"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves’ disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Dosage form specific issues</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878441"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults (children: 32%; adults: 2% to 6%).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F164606"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emtriva: 200 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emtriva: 10 mg/mL (170 mL) [contains edetate (edta) disodium, fd&amp;c yellow #6 (sunset yellow), methylparaben, propylene glycol, propylparaben; cotton candy flavor]</p></div>
<div class="block geq drugH1Div" id="F164593"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F164614"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Emtricitabine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $19.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Emtriva Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $21.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Emtriva Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F164609"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with or without food.</p></div>
<div class="block admp drugH1Div" id="F52612675"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food</p></div>
<div class="block use drugH1Div" id="F164607"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>HIV-1 infection, treatment:</b> Treatment of HIV-1 infection in combination with other antiretroviral agents.</p></div>
<div class="block off-label drugH1Div" id="F49228251"><span class="drugH1">Use: Off-Label: Adult</span><p>HIV-1 nonoccupational postexposure prophylaxis; HIV-1 occupational postexposure prophylaxis</p></div>
<div class="block cyt drugH1Div" id="F13299258"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F164600"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F164626"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases peak plasma concentrations, but does not alter the extent of absorption or overall systemic exposure. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49160665"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Contraception is not required to initiate or continue antiretroviral therapy (ART).</p>
<p style="text-indent:0em;">The Health and Human Services (HHS) perinatal HIV guidelines consider emtricitabine a preferred nucleoside reverse transcriptase inhibitor for patients with HIV who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Optimization of the health of the person who will become pregnant is recommended. Selection of or changes to a specific antiretroviral regimen prior to pregnancy should be done as part of a shared decision-making process. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Emtricitabine is a recommended component for pre-exposure prophylaxis (PrEP) in patients at risk for HIV infection who are planning a pregnancy. The partner without HIV should begin therapy 20 days prior to attempting conception. Up to 20 days of therapy are required to achieve protective drug concentrations in cervicovaginal tissue, therefore continued use of condoms to prevent HIV exposure is recommended during this time. PrEP should continue for 28 days after attempting conception or condomless sex exposure. Pregnancy testing should be done at baseline, then as indicated. PrEP with emtricitabine may continue if pregnancy occurs.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block pri drugH1Div" id="F164615"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Emtricitabine has a high level of transfer across the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">No increased risk of overall teratogenic effects has been observed according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small-for-gestational-age infants. Actual risks may be influenced by maternal factors, such as disease severity, gestational age at initiation of therapy, and specific ART regimen; therefore, close fetal monitoring is recommended. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children not diagnosed with HIV but who were exposed to ART in utero or as a neonate and develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential metabolic dysfunction.</p>
<p style="text-indent:0em;margin-top:2em;">The Health and Human Services (HHS) perinatal HIV guidelines consider emtricitabine a preferred nucleoside reverse transcriptase inhibitor (NRTI) for pregnant patients with HIV who are antiretroviral-naive, who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). In addition, patients who become pregnant while taking emtricitabine may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">The HHS perinatal HIV guidelines consider emtricitabine with tenofovir disoproxil fumarate or tenofovir alafenamide to be a preferred NRTI backbone for initial therapy in antiretroviral-naive patients who are pregnant. The guidelines also consider emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide a recommended dual NRTI backbone in regimens for patients who are HIV/hepatitis B virus-coinfected and pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Emtricitabine is a recommended component for pre-exposure prophylaxis (PrEP) in uninfected patients at risk for HIV infection who are pregnant. Emtricitabine is also a preferred component of an initial regimen when early (acute/recent) HIV infection is detected during pregnancy; genotyping may be required if the person had prior use of long acting cabotegravir for PrEP.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of emtricitabine are not significantly altered during pregnancy and dose adjustments are not needed.</p>
<p style="text-indent:0em;margin-top:2em;">ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of detection, and reduce the risk of perinatal transmission. Selection of or changes to a specific antiretroviral regimen during pregnancy should be done as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitoring of patients who are pregnant is more frequent than in patients who are not pregnant. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Health care providers should enroll all patients exposed to antiretroviral medications during pregnancy in the Antiretroviral Pregnancy Registry (1-800-258-4263). Enrollment should be done as early in pregnancy as possible.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for pregnant patients with HIV and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block brc drugH1Div" id="F164616"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations may be higher than those in the maternal serum. Emtricitabine can be detected in the serum of breastfed infants.</p>
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine is a recommended component of an initial regimen when early (acute/recent) HIV infection is detected in patients who are breastfeeding. Breastfeeding should be interrupted and not continued if infection is confirmed. Milk may be expressed and stored while waiting for confirmation.</p>
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine is a recommended component for pre-exposure prophylaxis (PrEP) in uninfected patients at risk for HIV infection who are breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Maintaining maximum viral suppression during pregnancy and postpartum decreases but does not eliminate the risk of HIV transmission via breast milk. In addition, multiclass-resistant virus has been detected in breastfeeding infants who acquire HIV despite maternal therapy. In the United States, where formula is usually accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, the Health and Human Services perinatal HIV guidelines do not recommend breastfeeding for patients with HIV when safer infant feeding options are available. Persons with HIV who maintain an undetectable viral load while taking antiretroviral therapy (ART) should evaluate infant feeding options (formula, banked donor milk, or breastfeeding) as part of a shared decision-making process (if breastfeeding is being considered, see guidelines for measures to reduce the risk of HIV transmission). When the HIV status at delivery is not known, breastmilk may be expressed and stored until a negative test is available. If HIV infection is diagnosed after breastfeeding has been initiated, breastfeeding should be discontinued immediately. Breastfeeding is not recommended for persons with HIV who are not taking ART and/or who do not have sustained viral suppression.</p>
<p style="text-indent:-2em;margin-left:2em;">Information is available for counseling and managing patients with HIV who are considering breastfeeding (1-888-448-8765). In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth (HHS [perinatal] 2023).</p></div>
<div class="block mop drugH1Div" id="F164604"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Viral load, CD4, liver function tests; serum creatinine; hepatitis B testing is recommended prior to or when initiating therapy.</p></div>
<div class="block pha drugH1Div" id="F164595"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nucleoside reverse transcriptase inhibitor; emtricitabine is a cytidine analogue which is phosphorylated intracellularly to emtricitabine 5'-triphosphate which interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication.</p></div>
<div class="block phk drugH1Div" id="F164611"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid, extensive</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;4%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Converted intracellularly to the active triphosphate form; undergoes minimal biotransformation via oxidation and glucuronide conjugation</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsule: 93%; solution: 75%; <b>Note:</b> Relative bioavailability of solution to capsule: 80%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Elimination half-life (emtricitabine):</p>
<p style="text-indent:-2em;margin-left:6em;">Single dose: 11 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Multiple dose: 7.9 to 9.5 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 0 to 3 months (n=20; median age: 26 days): 12.1 ± 3.1 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 3 to 24 months (n=14): 8.9 ± 3.2 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Children 25 months to 6 years (n=19): 11.3 ± 6.4 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Children 7 to 12 years (n=17): 8.2 ± 3.2 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents 13 to 17 years (n=27): 8.9 ± 3.3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Emtricitabine: 10 hours; Intracellular half-life (emtricitabine 5'-triphosphate): 39 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (86% primarily as unchanged drug, 13% as metabolites, 9% of dose as oxidative metabolite; 4% as glucuronide metabolite); feces (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Renal clearance is greater than creatinine clearance; thus, emtricitabine may be eliminated by both glomerular filtration and active tubular secretion</p></div>
<div class="block phksp drugH1Div" id="F51154037"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: C<sub>max</sub> and AUC are increased in patients with CrCl &lt;50 mL/minute. In patients on hemodialysis, emtricitabine exposure was increased 5.5 times compared to patients with normal kidney function, although no overt toxicity was reported (Eron 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Exposure is similar to adults. In neonates, the AUC was similar to the AUC observed in children at least 3 months to 17 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F164618"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Xin luo shu</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Emtricitabina</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Emtriva | Evotag | Kyvyr | Landtricib | Tesianier</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Emtricitabine tl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Emtriva</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37061778">
<a name="37061778"></a>Arshad I, Gandhi M, Gossai M, Feinstein A. Acute immune reconstitution inflammatory syndrome-HBV flare in an HIV/HBV coinfected patient after antiretroviral therapy initiation: case report and literature review. <i>Am J Case Rep</i>. 2023;24:e939210. doi:10.12659/AJCR.939210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/37061778/pubmed" id="37061778" target="_blank">37061778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14609348">
<a name="14609348"></a>Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. <i>Drugs</i>. 2003;63(22):2413-2424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/14609348/pubmed" id="14609348" target="_blank">14609348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benson.1">
<a name="Benson.1"></a>Benson CA, Kaplan JE, Masur H, et al, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents: Recommendations From CDC, The National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America," <i>Clin Infect Dis</i>, 2005, 40(Suppl 3):131-235.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cahn.1">
<a name="Cahn.1"></a>Cahn P, Raffi F, Saag M, et al, “Virologic Efficacy and Patterns of Resistance Mutations in ART-Naive Patients Receiving Combination Therapy with Once-Daily (QD) Emtricitabine Compared to Twice-Daily (BID) Stavudine in a Randomized, Double-blind, Multi-center Clinical Trial (Poster 606),” Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Available at http://www.retroconference.org/2003/CD/Abstract/606.htm
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS). Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>. Published April 18, 2016. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Emtriva.1">
<a name="Emtriva.1"></a>Emtriva (emtricitabine) [prescribing information]. Foster, CA: Gilead Sciences; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30555051">
<a name="30555051"></a>Eron JJ Jr, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.<i> Lancet HIV</i>. 2018:S2352-S3018(18)30296-0. doi:10.1016/S2352-3018(18)30296-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/30555051/pubmed" id="30555051" target="_blank">30555051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DOR.1">
<a name="DOR.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15977972">
<a name="15977972"></a>Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. <i>Drugs</i>. 2005;65(10):1427-1448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/15977972/pubmed" id="15977972" target="_blank">15977972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15922478">
<a name="15922478"></a>Gish RG, Trinh H, Leung N, et al, "Safety and Antiviral Activity of Emtricitabine (FTC) for the Treatment of Chronic Hepatitis B Infection: A Two-Year Study," <i>J Hepatol</i>, 2005, 43(1):60-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/15922478/pubmed" id="15922478" target="_blank">15922478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2018. Available at <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>HHS. Updated Guidelines for Antiretroviroal Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. Available at <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840965">
<a name="30840965"></a>Howard MD, Sim S. A novel association between antiretroviral therapy and drug-induced immune thrombocytopenia purpura. <i>Acta Haematol</i>. 2019;141(3):199-200. doi:10.1159/000496325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/30840965/pubmed" id="30840965" target="_blank">30840965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, Gomaa A, Panlilio AL; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. <i>Infect Control Hosp Epidemiol</i>. 2013;34(9):875-892. doi: 10.1086/672271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30648039">
<a name="30648039"></a>Lozier MR, Sanchez AM, Reyes R. Eosinophilic colitis associated with emtricitabine/tenofovir. <i>Cureus</i>. 2018;10(10):e3498. doi:10.7759/cureus.3498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/30648039/pubmed" id="30648039" target="_blank">30648039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31616574">
<a name="31616574"></a>Manickchund N, du Plessis C, John MA, et al. Emtricitabine-induced pure red cell aplasia. <i>South Afr J HIV Med</i>. 2019;20(1):983. doi:10.4102/sajhivmed.v20i1.983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/31616574/pubmed" id="31616574" target="_blank">31616574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27646953">
<a name="27646953"></a>Mapesi H, Ramírez A, Tanner M, Hatz C, Letang E; KIULARCO Study Group. Immune reconstitution inflammatory syndrome associated with dermatophytoses in two HIV-1 positive patients in rural Tanzania: a case report. <i>BMC Infect Dis</i>. 2016;16:495. doi:10.1186/s12879-016-1824-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/27646953/pubmed" id="27646953" target="_blank">27646953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16080074">
<a name="16080074"></a>Mondou E, Sorbel J, Anderson J, Mommeja-Marin H, Rigney A, Rousseau F. Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine. <i>Clin Infect Dis</i>. 2005;41(5):e45-e47. doi:10.1086/432581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/16080074/pubmed" id="16080074" target="_blank">16080074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Partosh.1">
<a name="Partosh.1"></a>Partosh D, Sherman EM, Eckardt PA, Unger N, Montalvo S. Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: a case report. <i>Int J STD AIDS</i>. 2023;34(2):139-141. doi:10.1177/09564624221140949</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27673443">
<a name="27673443"></a>Post FA, Tebas P, Clarke A, et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. <i>J Acquir Immune Defic Syndr</i>. 2017;74(2):180-184. doi:10.1097/QAI.0000000000001186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/27673443/pubmed" id="27673443" target="_blank">27673443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26627107">
<a name="26627107"></a>Pozniak A, Arribas JR, Gathe J, et al; GS-US-292-0112 Study Team. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. <i>J Acquir Immune Defic Syndr</i>. 2016;71(5):530-537. doi:10.1097/QAI.0000000000000908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/26627107/pubmed" id="26627107" target="_blank">26627107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html</a>. Accessed December 30, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16323102">
<a name="16323102"></a>Saag MS, "Emtricitabine, A New Antiretroviral Agent With Activity Against HIV and Hepatitis B Virus," <i>Clin Infect Dis</i>, 2006, 42(1):126-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/16323102/pubmed" id="16323102" target="_blank">16323102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21369776">
<a name="21369776"></a>Shirasaka T, Tadokoro T, Yamamoto Y, et al. Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. <i>J Infect Chemother</i>. 2011;17(5):602-608. doi:10.1007/s10156-011-0222-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/21369776/pubmed" id="21369776" target="_blank">21369776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36373751">
<a name="36373751"></a>Sidman EF, Ondrush NM. Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis. <i>Am J Health Syst Pharm</i>. 2023;80(9):e92-e97. doi:10.1093/ajhp/zxac339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/36373751/pubmed" id="36373751" target="_blank">36373751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated December 18, 2019. Accessed December 18, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated January 20, 2022. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24492366">
<a name="24492366"></a>Valade E, Tréluyer JM, Bouazza N, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. <i>Antimicrob Agents Chemother</i>. 2014;58(4):2256-2261. doi:10.1128/AAC.02058-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/24492366/pubmed" id="24492366" target="_blank">24492366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29534653">
<a name="29534653"></a>Van Slyke L, Scott M. Acute trigeminal neuralgia associated with initiation of emtricitabine/tenofovir for HIV pre-exposure prophylaxis. <i>J Int Assoc Provid AIDS Care</i>. 2018;17:2325958218760846. doi:10.1177/2325958218760846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/29534653/pubmed" id="29534653" target="_blank">29534653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693538">
<a name="14693538"></a>Wang LH, Wiznia AA, Rathore MH, et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. <i>Antimicrob Agents Chemother</i>. 2004;48(1):183-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/14693538/pubmed" id="14693538" target="_blank">14693538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36504313">
<a name="36504313"></a>Waters L, Winston A, Reeves I, et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. <i>HIV Med</i>. 2023:3-115. doi:10.1111/hiv.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/36504313/pubmed" id="36504313" target="_blank">36504313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34076616">
<a name="34076616"></a>Wood BR, Pozniak AL. Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance! <i>AIDS</i>. 2021;35(8):1305-1307. doi:10.1097/QAD.0000000000002903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/34076616/pubmed" id="34076616" target="_blank">34076616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi: 10.1111/j.1525-139X.2007.00280.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emtricitabine-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8594 Version 230.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
